Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Oncology
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| erlotinib 150/100 mg | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer?
BioSniper tracks 1 drug in development for Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer across 1 company.
How many clinical trials target Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer?
There are 1 clinical trial targeting Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer tracked by BioSniper.
Deep-dive into Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis